IE
BEAM icon

Israel Englander’s Beam Therapeutics BEAM Stock Holding History

Israel Englander’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72M Buy
+50,000
New +$1.51M ﹤0.01% 3937
2026
Q1 		– Sell
-150,000
Closed -$4.16M – 5714
2025
Q4 		$4.16M Buy
+150,000
New +$3.83M ﹤0.01% 3210

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Israel Englander's BEAM Position: Q2 2026 in Review

Israel Englander increased its Beam Therapeutics (BEAM) stake by 54% in Q2 2026, buying an estimated $363K and bringing the position to 34,260 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #4210.

Israel Englander first reported a position in BEAM in Q1 2020 and has held it in 25 quarters since. The position peaked at $33.1M in Q1 2022. 275 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Israel Englander held 34,260 shares of Beam Therapeutics worth $1.18M as of Q2 2026.
  • Israel Englander bought 12,026 Beam Therapeutics shares in Q2 2026, an estimated $363K.
  • Beam Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4210 holding.
  • Israel Englander first reported a position in Beam Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Israel Englander's Beam Therapeutics position peaked at $33.1M in Q1 2022.
  • 275 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.